Kala Pharmaceuticals reported a net loss of $15.6 million, or $0.63 per share, for the third quarter of 2018 compared with a net loss of $10.2 million, or $0.56 per share, a year ago, according to a press release.
Research and development costs stayed at $7 million year-over-year, whereas general and administrative costs increased from $2.5 million in 2017’s third quarter to $8.5 million in 2018. The company attributed the increase to commercial-related costs in anticipation of the launch of Inveltys (loteprednol etabonate ophthalmic suspension 1%) in early 2019.
Kala (Read more...)
Uncategorized